Background:High intensity statin therapy is currently recommended for primary prevention of ASCVD in patients with severe hyperlipidemia (HLD), defined as low-density lipoprotein cholesterol (LDL-C) of ≥190 mg/dL. We examined statin use for patients with severe HLD and associated ASCVD outcomes ...
When compared with individuals with zero calcification, those with a CAC score > 400 were significantly more likely to be prescribed a statin, including high-intensity therapy, and aspirin. Free Testing Once Disparaged To TCTMD, Rajagopalan said free CAC screening programs can help provide ...
ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial[J].Lancet. 2022;400(10349):380-390. [13] S...
As a monotherapy, it has been studied on top of high intensity statins and was around 18%. Some of us have used very low doses, 5 mg 3 times a week of rosuvastatin, which was given around 25%. Each patient has a different response, and we presented this data recently. The ...
SummaryWhile high-intensity statins remain the first-line treatment to prevent recurrent ASCVD events in secondary prevention patients, ezetimibe and PCSK9 inhibitors are evidence-based non-statin agents that can be used when residual on top of maximally tolerated statin therapy in patients deemed to ...